Cellectar Biosciences

-$0.02 (-1.43%) As of 7:27 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.

About CLRB

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detects tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.

CEO
James V. Caruso
Employees
11
Headquarters
Florham Park, New Jersey
Founded
1996

CLRB Key Statistics

Market Cap
78.25M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
690.69K
High Today
$1.05
Low Today
$1.01
Open Price
$1.03
Volume
966.64K
52 Week High
$2.98
52 Week Low
$1.01

CLRB Earnings

-$0.42
-$0.28
-$0.14
-$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 17, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure